CompletedNCT00500149
A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)
Medication studyAges 6–12United States
Understand this study
Who was this study for?
Listed age limits: 6 years to 12 years.
- Listed locations
- Little Rock, United States · Irvine, United States and 6 more locationsSee all locations and recruitment
- Activities
- Medication described in the protocol · Placebo comparator
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateStarted: June 13, 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 129
- Sponsor
- Shire
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 6 Years to 12 Years
- Official registry ID
- NCT00500149
- Official title
Show the full official title
A Phase IIIb, Randomized, Double-Blind, Multi-Center, Placebo- Controlled, Dose-Optimization, Cross-Over, Analog Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention-Deficit/Hyperactivity Disorder
Recruitment & locations
CompletedLittle Rock · Irvine · Wildomar
5 more locations
- Overland Park
- Las Vegas
- Durham
- Houston
- Lubbock
Questions about this study
Who is behind this study?
The study sponsor is Shire.
Did this study involve medication?
Yes. The study involved medication, including Vyvanse (lisdexamfetamine dimesylate) and Placebo.
Who was this study for?
Listed age limits: 6 years to 12 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me